Loading data for VCYT — first visit, this takes a few seconds.

알림

Veracyte Inc. (VCYT)

NasdaqGM: VCYT · 실시간 가격 · USD

41.48

+0.80 (1.97%)

종가 기준: Aug 18, 2026, 3:59 PM

1.97% (1D)

매수호가	33.3
시가총액	3.33B
매출 (ttm)	561.9M
순이익 (ttm)	114.48M
베타	1.94
EPS (ttm)	1.4
P/E (ttm)	29.6
선행 P/E	21.27
P/B (ttm)	2.51
P/S (ttm)	5.93
Earnings Date	Nov 3, 2026

매도호가	59.52
거래량	428,486
평균 거래량 (20일)	1,334,545
시가	41.92
전일 종가	40.68
일중 범위	40.09 - 42.46
52주 범위	28.25 - 60.91
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

VCYT 소개

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nC...

[더 보기]

산업 Diagnostics & Research

섹터 Healthcare

IPO 일자 Oct 30, 2013

직원 수 755

상장 거래소 NasdaqGM

티커 VCYT

웹사이트 https://www.veracyte.com

전체 기업 정보

재무 실적

2025년 Veracyte의 매출은 517.14M로, 전년 445.76M 대비 16.01% 증가했습니다. 순이익은 66.35M로, 174.89% 증가했습니다.

재무제표

어닝 서프라이즈

Veracyte가 Jul 30, 2026에 분기 실적을 발표했습니다:

매출 $150.32M 예상치 하회 $0, 및 15.49% 전년 대비 성장.

EPS 0.54 예상치 상회 0.11, 및 22.73% 전년 대비 성장.

다음 실적 발표

Veracyte Inc.의 실적 발표 예정일은 Nov 3, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · MarketBeat

Veracyte Q2 Earnings Call Highlights

Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD r...

2주 전 · Simply Wall St.

Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?

Veracyte (VCYT) is back in focus after raising its 2026 revenue guidance to a range of US$590 million to US$596 million, and releasing detailed second quarter and first half earnings results. See our ...

2주 전 · GuruFocus.com

Veracyte Inc (VCYT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Launches ...

Veracyte Inc (VCYT) raises full-year guidance after delivering 15% revenue growth and launching Prosigna and TrueMRD, positioning for long-term expansion.

2주 전 · Zacks

Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of +25.58% and +4.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2주 전 · Insider Monkey

Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S. market saw a...

2 페이지 중 1

Veracyte Inc. (VCYT)